Xinhua/Wang Ying/ Getty Images Exact Sciences soared as much as 33% on Tuesday after it announced it would acquire Thrive Earlier Detection for up to $2.15 billion.Thrive Earlier Detection is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.The deal will include an upfront payment of $1.7 billion in stock and cash, and up to an additional $450 million in potential milestone payments.In addition, Exact Sciences said it acquired Base Genomics for $410 million to expand its diagnostics technology.Visit the Business Insider homepage for more stories.Exact Sciences soared as much as 33% on Tuesday to record highs after the diagnostics company said it would acquire Thrive Earlier Detection for up to $2.15 billion in a stock and cash deal.Thrive Earlier Detection is a diagnostics company developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.

Topics:  i   read   exact   cancerseek   stock   cash   expand   tuesday   deal   payment   upfront   stages   announced   company   soared   test   
BING NEWS:
  • Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
    Source: Cancer Today. In the past, FDA generally applied an enforcement discretion approach for LDTs because most were manufactured in small volumes by local laboratories to meet the needs of ...
    04/2/2024 - 5:58 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News